Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry

This study has been completed.
Sponsor:
Collaborator:
Foundation for Medical Research in Krakow, Poland
Information provided by:
Jagiellonian University
ClinicalTrials.gov Identifier:
NCT00378391
First received: September 19, 2006
Last updated: June 19, 2007
Last verified: June 2007

September 19, 2006
June 19, 2007
November 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00378391 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry
European Registry on Patients With ST-Elevation MI Transferred for Mechanical Reperfusion (PCI)With a Special Focus on Upstream Use of Abciximab

EUROTRANSFER Registry is a prospective, international, web-based European Registry on Patients with ST-Elevation MI Transferred for Mechanical Reperfusion (PCI) with a Special Focus on Upstream Use of Abciximab.

This registry is designed to collect data on approximately 1800 patients during a 12 month enrollment period in up to 20 interventional cardiology centres with hospital transfer networks from all over Europe.

Analysis of this registry should allow to monitor transfer timelines of patients arriving to the cath-lab from the regional hospital with or without upstream start of abciximab and scheduled for mechanical reperfusion (PCI) as well as to monitor regional differences across Europe in regard to the impact that time of various stages of the treatment chain may have on clinical outcomes.

Not Provided
Observational
Observational Model: Defined Population
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Not Provided
Not Provided
  • ST-Elevation Myocardial Infarction
  • Acute Coronary Syndrome
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1800
February 2007
Not Provided

Inclusion Criteria:

PATIENTS:

  • All consecutive STEMI patients >=18years arriving to the Cath Lab hospital (invasive facility center) from transfer.

    • Transfer with respect to this registry is defined as patients that reach the Cath Lab hospital:

      1. transferred from a surrounding regional community hospitals that the Cath Lab hospital has an established referral pattern with or
      2. after being picked–up by an ambulance which is equipped/staffed to provide specific medical therapy (like prehospital thrombolysis or upstream abciximab). Usually these have a physician or specifically trained nurse on board.

        CENTRES:

    • Provide 24 hour/7 days on duty PCI service.
    • Has an established regional hospital referral network with >=8 patients/month arriving from transfer (as defined above).
    • A rate of >=10% of these transfer patients who receive upstream abciximab before or during transfer to the Cath Lab hospital. Start of abciximab in the ER or CCU of the Cath Lab hospital will not be considered as upstream start of abciximab.

Exclusion Criteria:

  • Patients who arrive to the Cath Lab from other pathways than those specified above (a. and b.), e.g. those who come by ambulances that do not provide specific medical therapy or arrive directly to the ER of the Cath Lab hospital by own feet/car will not be included in this registry.
  • Patients from controlled clinical trials shall be included as long as their actual treatment is fully known. Thus, participants from randomized trials with blinded treatment cannot be included in this registry.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Finland,   Germany,   Italy,   Poland,   Slovenia,   Spain,   Sweden
 
NCT00378391
H4S-PL-O067
Not Provided
Not Provided
Jagiellonian University
Foundation for Medical Research in Krakow, Poland
Principal Investigator: Dariusz Dudek, Assoc. Prof. Cardiac Catheterization Laboratories, Jagiellonian University Medical College
Study Chair: Zbigniew Siudak, MD Cardiac Catheterization Laboratories, Jagiellonian University Medical College
Study Director: Lukasz Partyka, MD, PhD Krakow Cardiovascular Research Institute
Jagiellonian University
June 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP